Product image of Infanrix-Ipv (Pertussis Toxoid Adsorbed On Aluminium Hydroxide, Pertussis Pertactin Adsorbed On Aluminium Hydroxid) supplied by GNH India

Infanrix-Ipv

Active Ingredient:
Pertussis Toxoid Adsorbed On Aluminium Hydroxide, Pertussis Pertactin Adsorbed On Aluminium Hydroxid
Origin:
EU

Infanrix-Ipv (Pertussis Toxoid Adsorbed On Aluminium Hydroxide, Pertussis Pertactin Adsorbed On Aluminium Hydroxid)

Pertussis Toxoid Adsorbed on Aluminium Hydroxide and Pertussis Pertactin Adsorbed on Aluminium Hydroxide, the active ingredients in Infanrix-Ipv, are a combined vaccine presented for intramuscular administration. The formulation is designed to stimulate protective antibody responses against pertussis bacteria, contributing to the primary immunization series for infants and young children in accordance with European vaccination programs.

GNH India supplies Infanrix-Ipv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring regulatory‑aligned distribution and cold‑chain logistics for this vaccine.

Manufacturer / TM Owner

Glaxosmithkline Biologicals S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Infanrix-Ipv is a combined vaccine that targets bacterial pathogens responsible for pertussis, diphtheria, tetanus and poliomyelitis.

  • Pertussis: induces protective antibodies to prevent whooping cough in infants and children.
  • Diphtheria: generates immunity against Corynebacterium diphtheriae toxin.
  • Tetanus: stimulates antibody production to neutralize tetanus toxin.
  • Poliomyelitis: provides active immunity to poliovirus types 1, 2 and 3.

How It Works

  • The vaccine contains pertussis toxoid and pertactin antigens adsorbed onto aluminium hydroxide particles. After intramuscular injection, the aluminium adjuvant enhances antigen presentation, prompting B‑cell activation and the generation of high‑affinity antibodies. This active immune response neutralizes the pertussis toxin and blocks bacterial adhesion, thereby preventing infection.

Side Effects

Infanrix-Ipv may cause a range of post‑vaccination reactions, most of which are mild and self‑limiting.

Common Side Effects

  • Injection site pain: soreness at the injection site.
  • Redness: localized erythema around the needle.
  • Swelling: mild edema at the site.
  • Fever: low‑grade temperature rise.
  • Irritability: increased fussiness in infants.
  • Loss of appetite: temporary reduction in feeding.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Seizures: rare febrile convulsions.
  • High fever: temperature above 40 °C.
  • Prolonged crying: excessive distress lasting more than three hours.
  • Hypotonic‑hyporesponsive episode: transient loss of muscle tone and reduced responsiveness.

Precautions & Warnings

Before administering Infanrix-Ipv, consider the following safety measures.

  • Age restriction: not for infants younger than six weeks.
  • Severe allergy: avoid if the patient has a known hypersensitivity to any vaccine component.
  • History of seizures: assess risk and monitor closely.
  • Immunocompromised status: consult a specialist before vaccination.
  • Concomitant vaccines: follow recommended interval guidelines.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Vaccines can interact with other agents that modify the immune system or antibody availability.

Major Interactions (Avoid)

  • Live viral vaccines: do not co‑administer within four weeks.
  • Immunoglobulin therapy: may diminish vaccine efficacy.
  • Blood products: can interfere with the immune response.

Moderate Interactions (Monitor Closely)

  • Corticosteroids: may blunt antibody production.
  • Chemotherapy agents: monitor immune response after vaccination.
  • Rituximab or other B‑cell depleting therapies: may reduce effectiveness.

Frequently Asked Questions

Infanrix-Ipv is a combined vaccine indicated for active immunization against pertussis, diphtheria, tetanus and poliomyelitis in infants and young children as part of routine vaccination schedules.

The pertussis toxoid and pertactin antigens are adsorbed onto aluminium hydroxide, which acts as an adjuvant to enhance immune recognition. This stimulates B‑cell activation and the production of antibodies that neutralize pertussis toxin and block bacterial adhesion.

The specific dosing schedule for Infanrix-Ipv is determined by the prescribing healthcare professional based on age, immunization history and local guidelines. No fixed regimen is provided here.

The safety of Infanrix-Ipv in pregnant or breastfeeding individuals has not been fully established. Use should be considered only if the potential benefit justifies any potential risk, and decisions are made by a qualified health professional.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping (including cold‑chain where needed) and import documentation.

Infanrix-Ipv combines pertussis antigens with diphtheria, tetanus and polio components, offering broader protection in a single injection compared with monovalent pertussis vaccines. Its aluminium‑hydroxide adjuvant is similar to many licensed combination vaccines, providing comparable immunogenicity and safety profiles.

Infanrix-Ipv must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Maintain the cold chain during transport and handling to preserve vaccine potency.

The vaccine is given by intramuscular injection, typically into the anterolateral thigh in infants or the deltoid muscle in older children, according to the immunization schedule prescribed by the healthcare provider.

Serious adverse events are rare but can include anaphylaxis, high‑grade fever, seizures, prolonged crying episodes, and hypotonic‑hyporesponsive episodes. Immediate medical attention is required if any of these occur after vaccination.

Infanrix-Ipv should be avoided in individuals with a known severe allergy to any vaccine component, in infants younger than six weeks, and in those who have experienced a severe reaction to a previous dose of the same vaccine.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Pertussis Toxoid Adsorbed On Aluminium Hydroxide, Pertussis Pertactin Adsorbed On Aluminium Hydroxid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT